These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10 AND Clinical Outcome
16 results:

  • 1. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
    Ozga M; Nicolet D; Mrózek K; Yilmaz AS; Kohlschmidt J; Larkin KT; Blachly JS; Oakes CC; Buss J; Walker CJ; Orwick S; Jurinovic V; Rothenberg-Thurley M; Dufour A; Schneider S; Sauerland MC; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; Subklewe M; Spiekermann K; Carroll AJ; Blum WG; Powell BL; Kolitz JE; Moore JO; Mayer RJ; Larson RA; Uy GL; Stock W; Metzeler KH; Grimes HL; Byrd JC; Salomonis N; Herold T; Mims AS; Eisfeld AK
    Leukemia; 2024 Jan; 38(1):45-57. PubMed ID: 38017103
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The clinical phenotype of germline RUNX1 mutations in relation to the accompanying somatic variants and RUNX1 isoform expression.
    Cabrerizo Granados D; Barbosa I; Baliakas P; Hellström-Lindberg E; Lundin V
    Genes Chromosomes Cancer; 2023 Nov; 62(11):672-677. PubMed ID: 37303296
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes.
    Konishi T; Sadato D; Toya T; Hirama C; Kishida Y; Nagata A; Yamada Y; Shingai N; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Okuyama Y; Harada H; Ohashi K; Harada Y; Doki N
    Sci Rep; 2023 Feb; 13(1):2641. PubMed ID: 36788335
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. sf3b1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
    Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Baer C; Kern W; Haferlach C
    Leukemia; 2022 Dec; 36(12):2894-2902. PubMed ID: 36261576
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation.
    Bracher S; Fuhrmann I; Jeromin S; Nadarajah N; Kern W; Haferlach T; Haferlach C; Stengel A
    Mol Biol Rep; 2022 Dec; 49(12):12247-12252. PubMed ID: 36169893
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
    van der Werf I; Wojtuszkiewicz A; Meggendorfer M; Hutter S; Baer C; Heymans M; Valk PJM; Kern W; Haferlach C; Janssen JJWM; Ossenkoppele GJ; Cloos J; Haferlach T
    Blood Adv; 2021 Sep; 5(17):3254-3265. PubMed ID: 34448812
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The protein landscape of chronic lymphocytic leukemia.
    Meier-Abt F; Lu J; Cannizzaro E; Pohly MF; Kummer S; Pfammatter S; Kunz L; Collins BC; Nadeu F; Lee KS; Xue P; Gwerder M; Roiss M; Hüllein J; Scheinost S; Dietrich S; Campo E; Huber W; Aebersold R; Zenz T
    Blood; 2021 Dec; 138(24):2514-2525. PubMed ID: 34189564
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
    Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
    Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. MYC copy number and mRNA expression in chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chornobyl NPP accident.
    Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
    Exp Oncol; 2020 Mar; 42(1):60-65. PubMed ID: 32231192
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Negative impact on clinical outcome of the mutational co-occurrence of sf3b1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).
    Martín I; Such E; Navarro B; Vicente A; López-Pavía M; Ibáñez M; Tormo M; Villamón E; Gómez-Seguí I; Luna I; Oltra S; Pedrola L; Sanz MA; Cervera J; Sanz G
    Leuk Lymphoma; 2017 Jul; 58(7):1686-1693. PubMed ID: 27771989
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts clinical outcome in Chronic Lymphocytic leukemia.
    Janovska P; Poppova L; Plevova K; Plesingerova H; Behal M; Kaucka M; Ovesna P; Hlozkova M; Borsky M; Stehlikova O; Brychtova Y; Doubek M; Machalova M; Baskar S; Kozubik A; Pospisilova S; Pavlova S; Bryja V
    Clin Cancer Res; 2016 Jan; 22(2):459-69. PubMed ID: 26240275
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
    Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
    Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.
    Shahjahani M; Mohammadiasl J; Noroozi F; Seghatoleslami M; Shahrabi S; Saba F; Saki N
    Cell Oncol (Dordr); 2015 Apr; 38(2):93-109. PubMed ID: 25563586
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model.
    Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Royo C; Navarro A; Pinyol M; Rozman M; Pereira A; Villamor N; Aymerich M; López C; Carrió A; Montserrat E
    Haematologica; 2014 Oct; 99(10):1599-604. PubMed ID: 24972773
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
    Puiggros A; Venturas M; Salido M; Blanco G; Fernandez-Rodriguez C; Collado R; Valiente A; Ruiz-Xivillé N; Carrió A; Ortuño FJ; Luño E; Calasanz MJ; Ardanaz MT; Piñán MÁ; Talavera E; González MT; Ortega M; Marugán I; Ferrer A; Gimeno E; Bellosillo B; Delgado J; Hernández JÁ; Hernández-Rivas JM; Espinet B; ;
    Genes Chromosomes Cancer; 2014 Sep; 53(9):788-97. PubMed ID: 24915757
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. clinical significance of sf3b1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
    Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.